Want to see IN:SAILIFE full AI Analyst Report?
Top Page
SAI Life Sciences Ltd.
(SAILIFE)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹1,752.00
▲(73.42% Upside)
Action:Reiterated
Date:08/11/26
The score is primarily supported by strong fundamental momentum (rapid revenue growth, improving margins/ROE, and low leverage) and solid bullish technicals (price above key moving averages with positive MACD). This is meaningfully offset by weak cash conversion (negative free cash flow) and a very expensive valuation (high P/E with no dividend yield provided), which increases downside risk if execution slows.
Positive Factors
Integrated CRDMO platform
An integrated offering across the drug-development lifecycle can deepen customer relationships and support repeat work as molecules advance. Serving discovery through manufacturing also broadens the addressable opportunity and allows the company to capture more value from successful programs over time.
Negative Factors
Persistent negative free cash flow
Despite improved operating cash generation, persistent negative free cash flow shows that accounting growth is not yet translating into surplus cash. Continued reinvestment or working-capital absorption could increase funding needs and constrain flexibility if expansion remains cash intensive.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated CRDMO platform
An integrated offering across the drug-development lifecycle can deepen customer relationships and support repeat work as molecules advance. Serving discovery through manufacturing also broadens the addressable opportunity and allows the company to capture more value from successful programs over time.
Read all positive factors
SAI Life Sciences Ltd. (SAILIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹336.56B
Dividend YieldN/A
Average Volume (3M)40.59K
Price to Earnings (P/E)92.3
Beta (1Y)1.07
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees5,224
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)17.17
Shares Outstanding212,313,260
10 Day Avg. Volume40,599
30 Day Avg. Volume40,592
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)8.20
Price to Sales (P/S)9.29
P/FCF Ratio-282.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,610.00Price Target Upside59.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)18.99
Revenue Forecast (FY)₹26.18B
SAI Life Sciences Ltd. Business Overview & Revenue Model
Company Description
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The c...
How the Company Makes Money
SAI Life Sciences makes money by providing fee-based outsourced R&D and manufacturing services to pharmaceutical and biotechnology customers. Its revenue model is typically a mix of (1) discovery and early development services, where customers pay...
SAI Life Sciences Ltd. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
84
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 22.50B | 21.92B | 16.96B |
| Gross Profit | 7.98B | 7.72B | 6.19B |
| EBITDA | 6.89B | 6.72B | 4.42B |
| Net Income | 3.62B | 3.49B | 1.70B |
Balance Sheet | |||
| Total Assets | 0.00 | 36.26B | 31.60B |
| Cash, Cash Equivalents and Short-Term Investments | 1.58B | 1.58B | 3.72B |
| Total Debt | 0.00 | 2.88B | 3.52B |
| Total Liabilities | -24.84B | 11.42B | 10.32B |
| Stockholders Equity | 24.84B | 24.84B | 21.28B |
Cash Flow | |||
| Free Cash Flow | -1.55B | -721.30M | -918.36M |
| Operating Cash Flow | 928.35M | 5.21B | 2.77B |
| Investing Cash Flow | -105.42M | -4.18B | -5.53B |
| Financing Cash Flow | 318.25M | -1.13B | 3.54B |
SAI Life Sciences Ltd. Technical Analysis
Positive
1010.25
Price Trends
1395.95
Positive
1271.85
Positive
1097.87
Positive
Market Momentum
64.69
Negative
61.32
Neutral
66.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SAILIFE, the sentiment is Positive. The current price of 1010.25 is below the 20-day moving average (MA) of 1516.39, below the 50-day MA of 1395.95, and below the 200-day MA of 1097.87, indicating a bullish trend. The MACD of 64.69 indicates Negative momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 66.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SAILIFE.
SAI Life Sciences Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹336.56B | 92.31 | ― | ― | ― | ― | |
67 Neutral | ₹281.25B | -89.18 | ― | 0.07% | 0.78% | -420.81% | |
66 Neutral | ₹301.97B | 60.66 | ― | 0.14% | 78.33% | 182.61% | |
60 Neutral | ₹1.06T | 97.23 | ― | 0.10% | 22.62% | 114.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹154.46B | 69.57 | ― | 0.33% | -3.41% | -56.45% | |
51 Neutral | ₹163.28B | 46.10 | ― | 0.49% | 16.27% | -23.50% |
* General Sector Average
IN:SAILIFE
SAI Life Sciences Ltd.
1,585.20
704.15
79.92%
IN:JUBLPHARMA
Jubilant Pharmova Limited
1,025.10
-90.23
-8.09%
IN:LAURUSLABS
Laurus Labs Ltd.
1,970.35
1,077.98
120.80%
IN:NEULANDLAB
Neuland Laboratories Ltd.
23,536.20
7,872.60
50.26%
IN:PPLPHARMA
Piramal Pharma Limited
211.25
7.60
3.73%
IN:SYNGENE
Syngene International Ltd.
382.65
-286.26
-42.79%
SAI Life Sciences Ltd. Corporate Events
Sai Life Sciences Publishes AGM Notice and E‑Voting Details
Aug 26, 2026
Sai Life Sciences Limited has notified the stock exchanges that it has published newspaper advertisements announcing its 27th Annual General Meeting. The AGM will be conducted on September 17, 2026, via video conference and other audio-visual mean...
Sai Life Sciences sets virtual 27th AGM, outlines e-voting schedule
Aug 24, 2026
Sai Life Sciences Ltd. has scheduled its 27th Annual General Meeting for September 17, 2026, at 10:30 a.m. IST, to be conducted via video conferencing and other audio-visual means in line with guidance from the Ministry of Corporate Affairs and SE...
Sai Life Sciences Sets September 17 Virtual AGM, Publishes E-Voting Details
Aug 24, 2026
Sai Life Sciences Limited has scheduled its 27th Annual General Meeting for September 17, 2026, at 10:30 a.m. India time, to be conducted via video conference and other audio-visual means in line with provisions of the Companies Act and SEBI listi...
Sai Life Sciences Allots 18,700 Shares Under ESOP 2008
Aug 6, 2026
Sai Life Sciences has allotted 18,700 fully paid-up equity shares with a face value of Rs.1 each under its Employees Stock Option Plan 2008, following board approval at a meeting on 6 August 2026. The shares, issued in dematerialized form and list...
Sai Life Sciences Posts Solid June-Quarter Results After Board Approval
Aug 6, 2026
Sai Life Sciences reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following approval by its board of directors at a meeting on August 6. The filing shows continued revenue generation and pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.